• Donate
  • Contact
Canadian Association of Pompe
  • Home
  • About Us
    • Portraits of Pompe
    • Our Partners
    • Newsletter
  • About Pompe
    • Talk Pompe
    • Webinars
  • Blog
  • Links
  • Connections
Select Page
Maze Therapeutics Starting Phase I Clinical Trial with MZE001, A Substrate Reduction Therapy

Maze Therapeutics Starting Phase I Clinical Trial with MZE001, A Substrate Reduction Therapy

by Victoria Radke | Feb 22, 2022 | News, Research & Studies

Recently, preclinical data were presented at the 18th Annual WORLDSymposium in San Diego, CA, supporting MZE001 as a treatment for Pompe disease.

Recent Posts

  • International Pompe Day 2022
  • Julie
  • Brad
  • Rare Disease Day 2022
  • Maze Therapeutics Starting Phase I Clinical Trial with MZE001, A Substrate Reduction Therapy
  • Terms
  • Privacy

Copyright © 2006 - 2023 Canadian Association of Pompe